Weekly Investment Analysts’ Ratings Updates for Teleflex (TFX)

Teleflex (NYSE: TFX) recently received a number of ratings updates from brokerages and research firms:

• 7/15/2026 – Teleflex had its price target raised by Mizuho from $140.00 to $145.00. They now have a “neutral” rating on the stock.
• 7/8/2026 – Teleflex is now covered by BMO Capital Markets. They set an “outperform” rating and a $159.00 price target on the stock.
• 7/8/2026 – Teleflex was upgraded by BMO Capital Markets to “strong-buy”.
• 6/27/2026 – Teleflex was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/24/2026 – Teleflex had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 6/8/2026 – Teleflex was upgraded by Piper Sandler from “neutral” to “overweight”. They now have a $160.00 price target on the stock, up from $140.00.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Monday, May 25th were paid a $0.34 dividend. The ex-dividend date of this dividend was Friday, May 22nd. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. Teleflex’s dividend payout ratio (DPR) is currently -5.96%.

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.